Opinion|Videos|July 20, 2023

JAK Inhibitor Overview and Relevance to AD

Christopher Bunick, MD, PhD, and Ruth Ann Vleugels, MD, MPD, MBA, discuss the method of action for Janus Kinase (JAK) inhibitors and the pathology of atopic dermatitis (AD).

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME